CL2023001225A1 - Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacion - Google Patents
Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacionInfo
- Publication number
- CL2023001225A1 CL2023001225A1 CL2023001225A CL2023001225A CL2023001225A1 CL 2023001225 A1 CL2023001225 A1 CL 2023001225A1 CL 2023001225 A CL2023001225 A CL 2023001225A CL 2023001225 A CL2023001225 A CL 2023001225A CL 2023001225 A1 CL2023001225 A1 CL 2023001225A1
- Authority
- CL
- Chile
- Prior art keywords
- preparation
- crystal form
- receptor agonist
- melanocortin receptor
- agonist compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940117029 Melanocortin receptor agonist Drugs 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001757 thermogravimetry curve Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a una forma cristalina IV de un compuesto representado por la fórmula química 1, a un método de preparación para el mismo, y a una composición farmacéutica que la comprende. La forma cristalina IV de un compuesto representado por la fórmula química 1, de la presente invención, puede ser especificada por un patrón XRD, perfil DSC y/o perfil TGA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200142400 | 2020-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001225A1 true CL2023001225A1 (es) | 2023-11-03 |
Family
ID=81384123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001225A CL2023001225A1 (es) | 2020-10-29 | 2023-04-27 | Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240010633A1 (es) |
| EP (1) | EP4219475A4 (es) |
| JP (1) | JP2023548161A (es) |
| CN (1) | CN116507614A (es) |
| AU (1) | AU2021367714B2 (es) |
| CA (1) | CA3195328A1 (es) |
| CL (1) | CL2023001225A1 (es) |
| CO (1) | CO2023006521A2 (es) |
| IL (1) | IL302429A (es) |
| MX (1) | MX2023004731A (es) |
| PE (1) | PE20240367A1 (es) |
| WO (1) | WO2022092914A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102485182B1 (ko) * | 2019-11-07 | 2023-01-06 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 작용제 |
| JP2024500966A (ja) * | 2020-12-22 | 2024-01-10 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉおよびその製造方法 |
| JP2024501829A (ja) * | 2020-12-22 | 2024-01-16 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の結晶形ｉｉｉおよびその製造方法 |
| KR20220090457A (ko) * | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅱ 및 이의 제조방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766191B2 (en) * | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| US7157463B2 (en) * | 2001-01-23 | 2007-01-02 | Eli Lilly And Company | Substituted piperidines/piperazines as melanocortin receptor agonists |
| AR044510A1 (es) | 2003-04-14 | 2005-09-14 | Merck & Co Inc | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
| JP4795965B2 (ja) * | 2003-11-12 | 2011-10-19 | エルジー・ライフ・サイエンシーズ・リミテッド | メラノコルチン受容体のアゴニスト |
| TWI332501B (en) | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| UA99555C2 (en) * | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| US11160891B2 (en) | 2017-02-08 | 2021-11-02 | Tilray, Inc. | Methods and apparatus for low-pressure radiant energy processing of cannabis |
| KR102485182B1 (ko) * | 2019-11-07 | 2023-01-06 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체 작용제 |
-
2021
- 2021-10-29 WO PCT/KR2021/015475 patent/WO2022092914A1/ko active Application Filing
- 2021-10-29 JP JP2023526431A patent/JP2023548161A/ja active Pending
- 2021-10-29 CA CA3195328A patent/CA3195328A1/en active Pending
- 2021-10-29 AU AU2021367714A patent/AU2021367714B2/en active Active
- 2021-10-29 MX MX2023004731A patent/MX2023004731A/es unknown
- 2021-10-29 CN CN202180073211.6A patent/CN116507614A/zh active Pending
- 2021-10-29 IL IL302429A patent/IL302429A/en unknown
- 2021-10-29 EP EP21886908.9A patent/EP4219475A4/en active Pending
- 2021-10-29 US US18/251,111 patent/US20240010633A1/en active Pending
- 2021-10-29 PE PE2023001516A patent/PE20240367A1/es unknown
-
2023
- 2023-04-27 CL CL2023001225A patent/CL2023001225A1/es unknown
- 2023-05-17 CO CONC2023/0006521A patent/CO2023006521A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL302429A (en) | 2023-06-01 |
| KR20220057473A (ko) | 2022-05-09 |
| MX2023004731A (es) | 2023-05-10 |
| AU2021367714A1 (en) | 2023-06-01 |
| CA3195328A1 (en) | 2022-05-05 |
| EP4219475A1 (en) | 2023-08-02 |
| PE20240367A1 (es) | 2024-03-04 |
| CO2023006521A2 (es) | 2023-08-18 |
| JP2023548161A (ja) | 2023-11-15 |
| WO2022092914A1 (ko) | 2022-05-05 |
| EP4219475A4 (en) | 2024-03-13 |
| US20240010633A1 (en) | 2024-01-11 |
| CN116507614A (zh) | 2023-07-28 |
| AU2021367714B2 (en) | 2024-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001225A1 (es) | Forma de cristal iv de compuesto agonista del receptor de melanocortina, y metodo de preparacion | |
| CL2023001223A1 (es) | Forma cristalina i del compuesto agonista del receptor de melanocortina y método para prepararlo | |
| CL2023001224A1 (es) | Forma cristalina ii del compuesto agonista de receptor de melanocortina y método de preparación | |
| CL2023001222A1 (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y método de preparación | |
| CL2020002277A1 (es) | Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734) | |
| CL2018001398A1 (es) | Marca de agua impresa | |
| AR079152A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR065272A1 (es) | Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| CO7350641A2 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados | |
| UY31803A (es) | Compuesto cristalino | |
| ECSP088620A (es) | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
| CU23820A3 (es) | (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y procedimiento de obtención | |
| PE20151884A1 (es) | Formas cristalinas de inhibidores de tirosina cinasa y sus sales | |
| ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| CL2021002263A1 (es) | Compuestos antibacterianos (solicitud divisional 202001147) | |
| ECSP10010499A (es) | Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida | |
| CL2023001221A1 (es) | Agonista del receptor de melanocortina-4 amorfo | |
| UY36746A (es) | Método para la síntesis de derivados de rapamicina | |
| CO2020006206A2 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción | |
| PE20211756A1 (es) | FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß | |
| CO6650398A2 (es) | Compuestos y composición farmacéutica para el tratamiento de los transtornos asociados a los receptores 5-ht1a y 5.ht2a |